iPower Inc. Announces $5 Million Registered Direct Offering
June 17, 2024 07:45 ET
|
iPower, Inc.
RANCHO CUCAMONGA, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a tech and data-driven online retailer and supplier of consumer home, pet and...
Amesite Announces Contract Renewal with EWIE Group of Companies
June 17, 2024 07:30 ET
|
Amesite Inc.
DETROIT, June 17, 2024 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education...
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
June 17, 2024 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the...
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
June 17, 2024 07:30 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
Venus Concept Announces Exclusive Strategic Supply Arrangement with Skin Laundry
June 17, 2024 07:30 ET
|
Venus Concept Inc.
TORONTO, June 17, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that it has entered a...
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
June 17, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024 07:30 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
nCino Deploying Banking Advisor, a Generative AI Solution to Drive New Efficiencies in Financial Institutions
June 17, 2024 07:30 ET
|
nCino, Inc.
Company's Gen AI tool, powered by nCino IQ (nIQ), delivers real-time intelligence and optimizes decision-making with data-driven insights for financial institutions across asset sizes and geographies ...
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
June 17, 2024 07:05 ET
|
BioRestorative Therapies, Inc
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) --...
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024 07:00 ET
|
Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...